Tradestie Institutional Equity Comparison Engine

NRIX vs BCAX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

NRIX Overall Edge

NRIX Captures Institutional Edge (3โ€“1 Pillars ยท 9โ€“0 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Nurix Therapeutics, Inc. Common stock (NRIX) driven by superior Valuation, Growth & Margin, Momentum & Technical while BCAX counters with relative strength in Options & Structure. Fundamentally, NRIX trades at N/M Forward P/E with 41.3% operating margin (+8426.3% YoY revenue) versus BCAX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, NRIX sits in BREAKDOWN (4th %ile IV; Dealer Gamma Walls on Pro) against BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner NRIX
NRIX N/M vs BCAX N/M Fwd P/E
Growth & Margin Winner NRIX
Op Margin 41.3% vs 0.0% ยท YoY +8426.3% vs +0.0%
Momentum & Technical Winner NRIX
1Y +18.5% vs -31.6% ยท 52W Pos 17% vs 8%
Options & Structure Winner BCAX
BREAKDOWN (4th %ile IV) vs BREAKDOWN (23rd %ile IV)
NRIX NASDAQ
Nurix Therapeutics, Inc. Common stock
Pharmaceutical Preparations
$14.73
-4.84% 1D
Market Cap $1.7B
1M Return -39.68%
1Y Return +18.5%
Forward P/E N/M
Unified AI Score
52.9 / 100 HOLD
Tech 55.0 Fund 58.0 Flow 64.0 Mom 55.0
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: NRIX +18.5% BCAX -31.63% Spread: +50.13 pp (NRIX Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
NRIX TTM Op. Margin: 41.3% BCAX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on NRIX vs BCAX. Trailing 12-month operating profitability (NRIX 41.3% vs BCAX 0.0%) and valuation multiples (NRIX N/M vs BCAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: NRIX (9) vs BCAX (0)
Institutional Metric NRIX BCAX Criterion Row Winner
Market Capitalization Scale $1.7B $665.2M Larger Scale NRIX
Trailing P/E Ratio Valuation 6.4x N/M Lower Multiple NRIX
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +8426.3% +0.0% Higher Growth NRIX
Operating Margin (TTM) Profitability 41.3% 0.0% Higher Margin NRIX
Net Profit Margin Profitability 42.0% 0.0% Higher Margin NRIX
Return on Equity (ROE) Capital Efficiency 44.0% -54.2% Higher ROE NRIX
52-Week Range Position Momentum 17% ($12โ€“$28) 8% ($8โ€“$31) Stronger Trend NRIX
Beta / 30D Volatility Risk Regime 0.95ฮฒ ยท 141% Vol 1.42ฮฒ ยท 184% Vol Lower Realized Risk NRIX
Unified Institutional Score Composite Signal 52.9 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite NRIX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full NRIX vs BCAX Buy Guide
NRIX BREAKDOWN
62d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 4th %ile
IV Regime Compressed (<25th %ile)
Live NRIX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither NRIX nor BCAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.